Share This Article:

Mean Platelet Volume and Prognosis of Unstable Angina

Abstract Full-Text HTML XML Download Download as PDF (Size:997KB) PP. 32-41
DOI: 10.4236/wjcd.2015.52005    4,563 Downloads   5,140 Views   Citations

ABSTRACT

Objective: Clopidogrel therapy is the standard of care in patients with unstable angina. However, a percentage of subjects are nonresponders to clopidogrel and this leads to increased adverse outcome. On the other way round, some responsive patients are exposed to bleeding complications. Detection of both in daily practice is important in order to tailor the treatment protocol. In this study we aimed to estimate the cutoff value of mean platelet volume (MPV) for both platelet responsiveness and bleeding risks. Methods: The study was planned as a prospective cohort study. A total number of 230 patients admitted to our CCU with unstable angina over a period of one year (from June 2013 to May 2014) were enrolled. Exclusion criteria were: severe anemia, throm-bocytopenia, myelodysplastic syndrome, coagulopathy and recent blood transfusion. In all patients clopidogrel was initially started and maintained during the hospital stay. Blood (2 ml) was collected in dipotassium EDTA tubes from all patients on the first day of admission by a clean puncture. Samples for MPV analysis were drawn on admission, and analyzed within 1 hour of admission after sampling by Beckman Caulter LH 780 Analyzer. Grouping was then done according to MPV of the patients into group (I) who had a low MPV less than or equal to 7.00 fl, and group (II) with MPV equal to or higher than 9.00 fl. Demographical and clinical variables of the patients were recorded. Routine laboratory parameters were also recorded. Clinical manifestations during the admission period were meticulously reported. Major complications as bleeding or, urgent need for percutaneous coronary intervention (PCI) were also studied. Results: Among the 230 patients analyzed, 175 patients (76%) were found to have MPV ≤7.00 fl (group (I)) and 55 patients (24%) had MPV ≥9.00 fl (group (II)) with mean ± SD MPV (8.4 ± 1.5 fl, vs 11.7 ± 1.2 fl respectively) (p < 0.001). Observation of clinical course during admission period revealed a statistically more significant clinical deterioration in group (II) than group (I) and the presence of more frequent AMI cases in group (II) having a high MPV. A high cutoff value of 9.7 fl for MPV was detected in prediction of clopidogrel nonresponsiveness (group (II)) with a sensitivity of 78.2% and specificity of 66.8%, and a low cutoff value for bleeding tendency lower than 6.3 fl was detected in group (I) with a sensitivity of 71.4% and specificity of 62.5%. Conclusion: This study showed that MPV can be used as a simple bedside predictor for detection of clopidogrel response in patients with unstable angina. And a cutoff value for both platelet responsiveness and risk of bleeding is now reached. This may lead to enhancement in our decision for early intervention and attention for bleeding risk during clopidogrel therapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Abdel-Rahman, T. (2015) Mean Platelet Volume and Prognosis of Unstable Angina. World Journal of Cardiovascular Diseases, 5, 32-41. doi: 10.4236/wjcd.2015.52005.

References

[1] Davi, G. and Patrono, C. (2007) Platelet Activation and Atherothrombosis. New England Journal of Medicine, 357, 2482-2494.
http://dx.doi.org/10.1056/NEJMra071014
[2] Trip, M.D., Cats, V.K., van Capelle, F.J.L., et al. (1990) Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction. New England Journal of Medicine, 322, 1549-1554.
http://dx.doi.org/10.1056/NEJM199005313222201
[3] Corash, L., Tan, H. and Grolnick, H.R. (1977) Heterogeneity of Human Whole Blood Platelet Subpopulations. I. Relationship between Buoyant Density, Cell Volume and Ultrastructure. Blood, 49, 71-87.
[4] Thompson, C.B., Eaton, K.A., Princiotta, S.M., et al. (1982) Size-Dependent Platelet Subpopulation: Relationship of Platelet Volume to Ultrastructure, Enzymatic Activity and Function. British Journal of Haematology, 50, 509-520.
http://dx.doi.org/10.1111/j.1365-2141.1982.tb01947.x
[5] Huszek, Z., Kochman, J., Filipiak, K.J., et al. (2005) Mean Platelet Volume on Admission Predicts Impaired Reperfusion and Long Term Mortality in Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 46, 284-290.
http://dx.doi.org/10.1016/j.jacc.2005.03.065
[6] Maden, O., Kacmaz, F., Selcuk, H., et al. (2009) Relationship of Admission Hematological Indexes with Myocardial Reperfusion Abnormalities in Acute ST Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Interventions. Canadian Journal of Cardiology, 25, e164-e168.
http://dx.doi.org/10.1016/S0828-282X(09)70090-X
[7] Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., et al. (2009) Platelet Reactivity after Clopidogrel Treatment Assessed with Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 53, 849-856.
http://dx.doi.org/10.1016/j.jacc.2008.11.030
[8] Antman, E.M., Wiviott, S.D., Murphy, S.A., Voitk, J., Hasin, Y., Widimsky, P., et al. (2008) Early and Late Benefits of Prasugrel in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction) Analysis. Journal of the American College of Cardiology, 51, 2028-2033.
http://dx.doi.org/10.1016/j.jacc.2008.04.002
[9] Cannon, C.P., Harrington, R.A., James, S., Ardissino, D., Becker, R.C., Emanuelsson, H., et al. (2010) Comparison of Ticagrelor with Clopidogrel in Patients with a Planned Invasive Strategy for Acute Coronary Syndromes: (PLATO): A Randomised Double-Blind Study. Lancet, 375, 283-293.
http://dx.doi.org/10.1016/S0140-6736(09)62191-7
[10] Siller-Matula, J.M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle-Karth, G., et al. (2013) Personalized Antiplatelet Treatment after Percutaneous Coronary Intervention: The MADONNA Study. International Journal of Cardiology, 167, 2018-2023.
http://dx.doi.org/10.1016/j.ijcard.2012.05.040
[11] Corash, L., Chen, H.Y., Levin, J., Baker, G., Lu, H. and Mok, Y. (1987) Regulation of Thrombopoiesis: Effects of the Degree of Thrombocytopenia on Megakaryocyte Ploidy and Platelet Volume. Blood, 70, 177-185.
[12] Storey, R.F., Newby, L.J. and Heptinstall, S. (2001) Effects of P2Y(1) and P2Y(12) Receptor Antagonists on Platelet Aggregation Induced by Different Agonists in Human Whole Blood. Platelets, 12, 443-447.
http://dx.doi.org/10.1080/09537100120085450
[13] Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators (2001) Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study. Lancet, 358, 527-533.
http://dx.doi.org/10.1016/S0140-6736(01)05701-4
[14] Steinhubl, S.R., Berger, P.B., Mann 3rd, J.T., Fry, E.T., DeLago, A., Wilmer, C., et al., Clopidogrel for the Reduction of Events during Observation (2002) Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Randomized Controlled Trial (CREDO). JAMA, 288, 2411-2420.
http://dx.doi.org/10.1001/jama.288.19.2411
[15] Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K., et al. (2001) Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine, 345, 494-502.
http://dx.doi.org/10.1056/NEJMoa010746
[16] Sabatine, M.S., Cannon, C.P., Gibson, C.M., López-Sendón, J.L., Montalescot, G., Theroux, P., et al., CLARITY- TIMI 28 Investigators (2005) Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine, 352, 1179-1189.
http://dx.doi.org/10.1056/NEJMoa050522
[17] Chen, Z.M., Jiang, L.X., Chen, Y.P., Peto, R., Collins, R., Jiang, L.X., et al., COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group (2005) Addition of Clopidogrel to Aspirin in 45,852 Patients with Acute Myocardial Infarction: Randomised Placebo-Controlled Trial. Lancet, 366, 1607-1621.
http://dx.doi.org/10.1016/S0140-6736(05)67660-X
[18] Güray, Y., Güray, ü. and Korkmaz, U. (2009) Clopidogrel Resistance. Anadolu Kardiyol Derg, 9, 231-237.
[19] Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., et al. (2004) Clopidogrel Resistance Is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients with Acute Myocardial Infarction. Circulation, 109, 3171-3175.
http://dx.doi.org/10.1161/01.CIR.0000130846.46168.03
[20] Park, Y., Schone, N. and Harris, W. (2002) Mean Platelet Volume as an Indicator of Platelet Activation: Methodological Issues. Platelets, 13, 301-306.
http://dx.doi.org/10.1080/095371002220148332
[21] Chu, S.G., Berger, R.C., Bhatt, D.L., Eikelboom, J.W., Konkle, B., Mohler, E.R., et al. (2010) Mean Platelet Volume as a Predictor of Cardiovascular Risk: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Haemostasis, 8, 148-156.
http://dx.doi.org/10.1111/j.1538-7836.2009.03584.x
[22] Deutsch, V. and Tomer, A. (2006) Megakaryocyte Development and Platelet Production. British Journal of Haematology, 134, 453-466.
http://dx.doi.org/10.1111/j.1365-2141.2006.06215.x
[23] Senaran, H., Ileri, M., Altinbas, A., KoSar, A., Yetkin, E., Oztürk, M., Karaaslan, Y. and Kirazli, S. (2001) Thrombopoietin and Mean Platelet Volume in Coronary Artery Disease. Clinical Cardiology, 24, 405-408.
http://dx.doi.org/10.1002/clc.4960240511
[24] Yasar, A.S., Bilen, E., Yuksel, I., Arslantas, U., Karakas, F., Kirbas, O. and Bilge, M. (2010) Association between Admission Mean Platelet Volume and Coronary Patency after Thrombolytic Therapy for Acute Myocardial Infarction. Turk Kardiyoloji Dernegi Arsivi, 38, 85-89.
[25] Martin, J.F., Bath, P.M. and Burr, M.L. (1991) Influence of Platelet Size on Outcome after Myocardial Infarction. Lancet, 338, 1409-1411.
http://dx.doi.org/10.1016/0140-6736(91)92719-I
[26] Dogan, A., Aksoy, F., Icli, A., Arslan, A., Varol, E., Uysal, B.A., Ozaydin, M. and Erdogan, D. (2012) Mean Platelet Volume Is Associated with Culprit Lesion Severity and Cardiac Events in Acute Coronary Syndromes without ST Elevation. Blood Coagulation & Fibrinolysis, 23, 324-330.
http://dx.doi.org/10.1097/MBC.0b013e328352cb21
[27] Klovaite, J., Benn, M., Yazdanyar, S. and Nordestgaard, B.G. (2011) High Platelet Volume and Increased Risk of Myocardial Infarction: 39531 Participants from the General Population. Journal of Thrombosis and Haemostasis, 9, 49-56.
http://dx.doi.org/10.1111/j.1538-7836.2010.04110.x
[28] Kuliczkowski, W., Witkowski, A., Polonski, L., Watala, C., Filipiak, K., Budaj, A., et al. (2009) Interindividual Variability in the Response to Oral Antiplatelet Drugs: A Position Paper of the Working Group on Antiplatelet Drugs Resistance Appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, Endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 30, 426-435.
http://dx.doi.org/10.1093/eurheartj/ehn562
[29] Zareifar, S., Farahmand Far, M.R., Golfeshan, F. and Cohan, N. (2014) Changes in Platelet Count and Mean Platelet Volume during Infectious and Inflammatory Disease and Their Correlation with ESR and CRP. Journal of Clinical Laboratory Analysis, 28, 245-248.
http://dx.doi.org/10.1002/jcla.21673
[30] Taglieri, N., Saia, F., Rapezi, C., Marrozzini, C., Bacchi Reggiani, M.L., Palmerini, T., et al. (2011) Prognostic Significance of Mean Platelet Volume on Admission in an Unselected Cohort of Patients with Non ST-Segment Elevation Acute Coronary Syndrome. Thrombosis and Haemostasis, 106, 132-140. http://dx.doi.org/10.1160/TH10-12-0821

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.